Peter Aaby1, Jens Nielsen2, Christine S Benn2, Jean-François Trape3. 1. Institut de Recherche pour le Développement (IRD), Laboratoire de Paludologie, Epidémiologie et Zoologie afrotropicales, BP 1386, Dakar, Senegal Bandim Health Project, Indepth Network, Apartado 861, Bissau, Guinea-Bissau p.aaby@bandim.org. 2. Research Center for Vitamins and Vaccines (CVIVA), Statens Serum Institut, Copenhagen, Denmark. 3. Institut de Recherche pour le Développement (IRD), Laboratoire de Paludologie, Epidémiologie et Zoologie afrotropicales, BP 1386, Dakar, Senegal.
Abstract
BACKGROUND: We examined the potential sex-differential and non-specific effects of bacille Calmette-Guérin (BCG), diphtheria-tetanus-pertussis (DTP) and measles vaccine (MV) in a rural area of Senegal. METHODS: The 4133 children born in the area between 1996 and 1999 were included in the study. Vaccinations were provided at three health centres. Vaccine information was collected through 3-monthly home visits. The survival analysis compared the effects of BCG and DTP according to the following sequence of vaccinations: BCG-first, BCG+DTP1-first, or DTP1-first. We compared DTP and MV between 9 and 24 months of age, as 9 months is the minimum age for MV. RESULTS: At 12 months the vaccination coverage was 44%, 46% and 9%, respectively, for BCG, DTP1 and MV. Most children received BCG+DTP1-first and this combination was associated with a significantly lower mortality rate ratio (MRR) of 0.69 (0.53-0.89) compared with unvaccinated children. There was no benefit for children receiving BCG-first or DTP1-first. The female-male MRR was 0.79 (0.64-0.96) among unvaccinated children, but was significantly inversed with 1.45 (1.00-2.10) for children receiving DTP vaccination (test of homogeneity, p=0.006). Children who had received DTP simultaneously with MV or DTP after MV had significantly higher mortality (MRR=2.59 [1.32-5.07]) compared with children having MV-only as their most recent vaccination. After 9 months, the female-male MRR was 0.61 (0.31-1.19) for measles-vaccinated children but remained 1.54 (1.03-2.31) for DTP-vaccinated children who had not received MV (p=0.01). CONCLUSIONS: The sequence of routine vaccinations is important for the overall impact on child survival and these vaccines are associated with sex-differential effects.
BACKGROUND: We examined the potential sex-differential and non-specific effects of bacille Calmette-Guérin (BCG), diphtheria-tetanus-pertussis (DTP) and measles vaccine (MV) in a rural area of Senegal. METHODS: The 4133 children born in the area between 1996 and 1999 were included in the study. Vaccinations were provided at three health centres. Vaccine information was collected through 3-monthly home visits. The survival analysis compared the effects of BCG and DTP according to the following sequence of vaccinations: BCG-first, BCG+DTP1-first, or DTP1-first. We compared DTP and MV between 9 and 24 months of age, as 9 months is the minimum age for MV. RESULTS: At 12 months the vaccination coverage was 44%, 46% and 9%, respectively, for BCG, DTP1 and MV. Most children received BCG+DTP1-first and this combination was associated with a significantly lower mortality rate ratio (MRR) of 0.69 (0.53-0.89) compared with unvaccinated children. There was no benefit for children receiving BCG-first or DTP1-first. The female-male MRR was 0.79 (0.64-0.96) among unvaccinated children, but was significantly inversed with 1.45 (1.00-2.10) for children receiving DTP vaccination (test of homogeneity, p=0.006). Children who had received DTP simultaneously with MV or DTP after MV had significantly higher mortality (MRR=2.59 [1.32-5.07]) compared with children having MV-only as their most recent vaccination. After 9 months, the female-male MRR was 0.61 (0.31-1.19) for measles-vaccinated children but remained 1.54 (1.03-2.31) for DTP-vaccinated children who had not received MV (p=0.01). CONCLUSIONS: The sequence of routine vaccinations is important for the overall impact on child survival and these vaccines are associated with sex-differential effects.
Authors: Syed Manzoor Ahmed Hanifi; Sofie Biering-Sørensen; Aksel Karl Georg Jensen; Peter Aaby; Abbas Bhuiya Journal: Hum Vaccin Immunother Date: 2020-06-23 Impact factor: 3.452
Authors: Jesper Kjærgaard; Nina M Birk; Thomas N Nissen; Lisbeth M Thøstesen; Gitte T Pihl; Christine S Benn; Dorthe L Jeppesen; Ole Pryds; Poul-Erik Kofoed; Peter Aaby; Gorm Greisen; Lone G Stensballe Journal: Pediatr Res Date: 2016-07-18 Impact factor: 3.756
Authors: Christine S Benn; Peter Aaby; Rob J W Arts; Kristoffer J Jensen; Mihai G Netea; Ane B Fisker Journal: Int J Epidemiol Date: 2015-07-02 Impact factor: 7.196
Authors: Julian P T Higgins; Karla Soares-Weiser; José A López-López; Artemisia Kakourou; Katherine Chaplin; Hannah Christensen; Natasha K Martin; Jonathan A C Sterne; Arthur L Reingold Journal: BMJ Date: 2016-10-13
Authors: Peter Aaby; Henrik Ravn; Ane B Fisker; Amabelia Rodrigues; Christine S Benn Journal: Trans R Soc Trop Med Hyg Date: 2016-11-17 Impact factor: 2.184
Authors: Susanne M A J Tielemans; Hester E de Melker; Susan J M Hahné; Anna G C Boef; Fiona R M van der Klis; Elisabeth A M Sanders; Marianne A B van der Sande; Mirjam J Knol Journal: BMJ Date: 2017-08-30
Authors: Paul Welaga; Abraham Hodgson; Cornelius Debpuur; Peter Aaby; Fred Binka; Daniel Azongo; Abraham Oduro Journal: Front Public Health Date: 2018-02-12